Oncolytics Biotech, Inc. (ONCY) stock has risen 173.02% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives ONCY stock a score of 70 out of a possible 100.
That rank is influenced by a fundamental score of 97. In addition to the average rating from Wall Street analysts, ONCY stock has a mean target price of 7.713. This means analysts expect the stock to gain 348.43% over the next 12 months. ONCY's rank also includes a short-term technical score of 89. The long-term technical score for ONCY is 25.
What's Happening with ONCY Stock Today
Oncolytics Biotech, Inc. (ONCY) stock has gained 2.69% while the S&P 500 has risen 0.28% as of 11:14 AM on Monday, Aug 17. ONCY has risen $0.05 from the previous closing price of $1.67 on volume of 231,442 shares. Over the past year the S&P 500 is up 15.69% while ONCY has risen 173.02%. ONCY lost -$0.78 per share in the over the last 12 months.